SpringWorks Therapeutics
SWTX
SWTX was delisted on the 30th of June, 2025.
135 hedge funds and large institutions have $3.69B invested in SpringWorks Therapeutics in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 60 increasing their positions, 36 reducing their positions, and 22 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 36
14% more capital invested
Capital invested by funds: $3.23B → $3.69B (+$457M)
1.53% more ownership
Funds ownership: 89.68% → 91.21% (+1.5%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
1% less funds holding
Funds holding: 137 → 135 (-2)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $231K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$20.6M |
| 2 |
BlackRock
New York
|
+$16.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$13.4M |
| 5 |
Jennison Associates
New York
|
+$9.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$16.5M |
| 2 |
O
OrbiMed
New York
|
-$10.8M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$8.35M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$8.28M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$6.06M |
SWTX Hedge Fund Activity: Q2 2021 in Review
135 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2021, worth a combined $3.69B — up 14% from $3.23B a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SWTX and 20 opened new positions — a net loss of 2 holders — while 36 trimmed existing stakes and 60 added.
The largest buyer was Bank of America, adding an estimated $20.6M. The largest seller was CAAS Capital Management, exiting entirely with an estimated $16.5M sold.
- 135 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2021, down from 137 in Q1 2021.
- Funds reported $3.69B of SpringWorks Therapeutics stock for Q2 2021, up 14% quarter-over-quarter.
- 20 funds opened new SpringWorks Therapeutics positions in Q2 2021 and 22 closed out, a net change of -2 holders.
- The largest SpringWorks Therapeutics buyer in Q2 2021 was Bank of America, an estimated $20.6M added.
- The largest SpringWorks Therapeutics seller in Q2 2021 was CAAS Capital Management, an estimated $16.5M sold.
Based on aggregated 13F filings for Q2 2021.